| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic progressive fibrosing interstitial lung disease of unknown cause that carries a dismal prognosis, with a 5-years survival of approximately 20%. There is no available therapy including corticosteroids. Recently, primary pulmonary hypertension(PPH) is reported to improve their prognosis owe to new medication, which express similar pathology to terminal IPF. Therefore, effective treatment of PPH is tried to apply to IPF treatment. We focused on phosphodiesterase(PDE) expression of IPF patients compared to normal lung. Westernblotting revealed the increased expression of PDE5A in IPF lung compared to normal lung. Immunohistochemistry showed localization of expressed PDE5A in fibroblasts. The result was different from our expectation that PDE5A is increased in vascular smooth muscle cells. The results obtained from this study suggests that increased expression of PDE5A may be related to progression of lung fibrosis itself.
|
